Full Press Release Details
Abeona Therapeutics Reports Second Quarter
2018 Financial Results and Business Highlights
Investor Conference Call on Friday, August 10th
YORK and CLEVELAND - August 09, 2018: Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical
company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial
results for the second quarter of 2018. The Company will host a call to update investors on recent clinical developments and quarter
financial results on Friday, August 10th at 10:00 am (Eastern). Interested parties are invited to participate in the
call by dialing 877-407-9210 (toll-free domestic) or 201-689-8049 (International) or via webcast http://www.investorcalendar.com/event/35041.
"The second quarter was marked by
continued progress in our clinical, pre-clinical and corporate initiatives," stated Carsten Thiel, Ph.D., Abeona's
CEO. "The strength of our lead programs, which continue to demonstrate robust and durable clinical effects, is underscored
by the achievement of additional regulatory designations and the recent appointment of key executives and Board members. Notably,
the opening of our in-house GMP manufacturing facility in Cleveland reinforces Abeona's ongoing commitment to transforming
patients' lives and bolsters our position for commercial readiness."
2nd Quarter Summary Financial
Abeona Recent Highlights:
"As we advance towards becoming a
key player in the development of novel breakthrough gene and cell therapies for rare genetic diseases, 2018 continues to be a year
of execution for Abeona," stated Steven H. Rouhandeh, Abeona's Executive Chairman.
About Abeona: Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB),
ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU),
an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201
(AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB),
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM , for next generation
product candidates. For more information, visit www.abeonatherapeutics.com.
Christine Silverstein
SVP, Finance & Investor Relations
Abeona Therapeutics Inc.
Berry & Company Public Relations
This press release contains
certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section
21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements
regarding our advancement towards becoming a key player in the development of novel breakthrough gene and cell therapies for rare
genetic diseases and that 2018 continues to be a year of execution. We have attempted to identify forward looking statements
by such terminology as "may," will," "anticipate," "believe," "estimate,"
"expect," "intend," and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and
uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize
our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and
global economic conditions; our belief that initial signals of biopotency and clinical activity, which suggest that ABO-102 successfully
reached target tissues throughout the body, including the central nervous system and the increased reductions in CNS GAG support
our approach for intravenous delivery for subjects with Sanfilippo syndromes, risks associated with data analysis and reporting,
and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and quarterly reports on Form
10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations
to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances
occurring after the date of this release, whether as a result of new information, future developments or otherwise.